Pharma BD Deal Intelligence

Dainippon Sumitomo Pharma Co., Ltd. / Boston Biomedical, Inc.

2012 · Acquisition/Merger · $2.6B · Complete

Announcement Sentiment

Skeptical

Dainippon Sumitomo acquired Boston Biomedical for $200M upfront plus up to $540M in development milestones and $1.89B in commercial milestones (~$2.63B total). Acquired cancer stem cell-targeting oncology pipeline (BBI608 entering Phase 3 CRC; BBI503 Phase 1 solid tumors).

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 10yr post-close.

Key facts

Announced Feb 29, 2012
Closed Apr 25, 2012
Deal value $2.6B
Deal type Acquisition/Merger
Therapeutic area Colorectal cancer, advanced solid tumors
Indications Colorectal cancer, advanced solid tumors
Key assets Napabucasin (BBI608) and BBI503
Mechanism Cancer stem cell pathway inhibitors (STAT3/cancer stemness kinases)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals